search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Evaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.


- candidate number15174
- NTR NumberNTR4086
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR23-jul-2013
- Secondary IDsFuTuRe 
- Public TitleEvaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.
- Scientific TitleEvaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.
- ACRONYMFuTuRe
- hypothesis18F-FDHT PET/CT is expected to be a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide
- Healt Condition(s) or Problem(s) studiedCastration-resistant prostate cancer
- Inclusion criteriaMain inclusion criteria:
1. Age 50 or older.
2. Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features.
3. Ongoing androgen deprivation therapy with a gonadotropin-releasing hormone analogue or bilateral orchidectomy.
4. Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bone disease.
5. Metastatic disease documented by bone lesions on bone scan or by measurable soft tissue disease by CT
6. No prior cytotoxic chemotherapy for prostate cancer.
7. Asymptomatic or mildly symptomatic from prostate cancer.
8. Written informed consent.
- Exclusion criteriaMain exclusion criteria:
1. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
2. Known or suspected brain metastasis or active leptomeningeal disease.
3. History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-mei-2014
- planned closingdate1-aug-2020
- Target number of participants60
- InterventionsEnzalutamide
- Primary outcomeDiagnostic accuracy of 18F-FDHT PET/CT as a predictor of treatment response
- Secondary outcomeComparison of 'treatment response and clinical survival endpoints' versus 'no treatment response and clinical survival endpoints'
- TimepointsStart 18F-FDHT PET/CT at baseline (prior to treatment), start enzalutamide at baseline, 18F-FDHT PET/CT after 4 weeks of treatment, follow-up visits on a monthly basis during the first year of the trial, afterwards once a quarter
- Trial web siteN/A
- statusrecruitement status not public
- CONTACT FOR PUBLIC QUERIESDr. I.J. Jong, de
- CONTACT for SCIENTIFIC QUERIESDr. I.J. Jong, de
- Sponsor/Initiator University Medical Center Groningen (UMCG)
- Funding
(Source(s) of Monetary or Material Support)
Center for Translational Molecular Medicine (CTMM)
- PublicationsN/A
- Brief summaryWorldwide prostate cancer is the second most frequently diagnosed cancer in men. While localized prostate cancer can be treated with curative intent, metastasized prostate cancer has palliative treatment options only. Endocrine deprivation therapy is the mainstay of treatment for patients with metastasized prostate cancer. In the end, prostate cancer progresses in the majority of patients because of progressive tumor growth despite endocrine deprivation therapy: castration-resistant prostate cancer (CRPC). As CRPC progresses, approximately 90% of patients will develop bone metastases, in contrast to lymph node metastases which develop in 20% to 25% of patients. The determination of response to treatment in patients with CRPC is predominantly plagued by the presence of non-measurable bone metastases. Positron Emission Tomography (PET) is emerging as a promising imaging modality to evaluate treatment options and therapeutic response timely, objectively and quantitatively. 16β-[18F]-fluoro-5α-dihydrotestosterone (18F-FDHT) images the androgen receptor with high binding affinity and selectivity. It is expected that 18F-FDHTPET/CT can give an indication of success or failure early in the treatment course as part of clinical management or within the context of clinical trials. Timely response management may adjust the duration of individual treatment according to its success. This is where the FuTuRe trial comes in. The primary objective is to evaluate 18F-FDHT PET/CT as a predictor of response in patients with CRPC who are to be treated with enzalutamide.
- Main changes (audit trail)31-3-2014: Changes in studyprotocol due to METC approval. - AB
- RECORD23-jul-2013 - 31-mrt-2014


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl